### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of .. 19 1

Atty Dkt. 2661-22

C# M#

CRAPO et al

TC/A.U.

1617

Examiner: Wang, S.

Filed: January 22, 2002

Serial No. 10/051,367

Title:

**CANCER THERAPY** 

Date: November 23, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

# ☐ Correspondence Address Indication Form Attached.

Fees are attached as calculated below:		
Total effective claims after amendment $0$ minus highest number previously paid for $20$ (at least $20$ ) = $0$ x \$ 18.00	\$	0.00
	Ψ	0.00
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 88.00	\$	0.00
If proper multiple dependent claims now added for first time, add \$300.00 (ignore improper)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$430.00/2 months; \$980.00/3 months)	\$	0.00
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$790.00) ☐ Please enter the previously unentered , filed ☐ Submission attached	\$	0.00
	Subtotal \$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract .  . Applicant claims "small entity" status Statement filed herewith	-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	180.00
Assignment Recording Fee (\$40.00)	\$	0.00
Other:		0.00

**TOTAL FEE ENCLOSED \$** 180.00

Mery J. Wilson

HT 1617

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

902118

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No. 6992 In re Patent Application of Atty. Ref.: CRAPO et al 2661-22 Serial No. 10/051,367 Group: 1617 Filed: January 22, 2002 Examiner: Wang, S. For: **CANCER THERAPY** Commissioner for Patents November 23, 2004 P.O. Box 1450 Alexandria, VA 22313-1450 Sir: INFORMATION DISCLOSURE STATEMENT 1. PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C X 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] 11/24/2004 MGEBREM1 00000079 10051367 \$180.00 180.00 OP

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

 $\boxtimes$ A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

01 FC:1806

CRAPO et al

Serial No.: 10/051,367 November 23, 2004

This paper is submitted in accordance with.						
	5.	37 (	CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]			
$\boxtimes$	6.	37 ( and	CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]			
		a)	The required Statement made in item 8 below; or			
	$\boxtimes$	b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.			
	7.		CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) ement and Rule 17(p) fee), but before final fee payment]; and			
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and			
		b)	The required Statement is stated in item 8 below.			
	8.	Stat	ement under 37 CFR 1.97(e)			
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or			

CRAPO et al

Serial No.: 10/051,367 November 23, 2004

- D) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

Mary J. Wilson

Reg. No. 32,955

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

# INFORMATION DISCLOSURE CITATION

Atty. Docket No.	Serial No.	
2661-22 OIPE	10/051,367	
Applicant	C. A.	
CRAPO NOV 2 3 201		
Filing Date \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	TC/A.U.	
January (Ex	1617	

(Use several sheets if necessary)		Filing Date \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		TC/A.U.					
	•	Janu	iary Fra	MARKON	1617	7		<u></u>	
-			•	TRADEM		<u> </u>			
	·		U.S. PATENT I	OCUMENTS				FILING	DATE
XAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS		
					1.	-	<u> </u>	<u> </u>	
					<u></u>	<del> </del>		<del> </del>	<del>.</del>
							<del> </del>	<del> </del>	
		<del></del>				<del> </del>		<del> </del> -	
								<del>                                     </del>	*****
					<del></del>	<u> </u>		<u> </u>	
	<del>                                     </del>				-			<del> </del>	
		* . ***		<u> </u>					
-						<u> </u>		<u> </u>	
		FO	REIGN PATENT	DOCUMENTS	i				
								TRANS	LATION
	DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	YES	NO
	WO 91/19977	12/1991		WIPO					
	-								
	OTHER DOC	UMENTS (	including Auth	or, Title, Date, I	Pertinent	pages, e	etc.)		
	Sonis et al, "AEOL 101	50, a cataly	tic antioxidant, re-	duces the incident	ce and dur	ation of ra	diation-indu	ced oral n	nucosit
	in a hamster", European	n Journal of	Cancer 37:S361 (	2001) - Abstract					
	Konorev et al, "Cell-Pe	rmeable Sup	peroxide Dismutas	se and Glutathion	e Peroxida	se Mimet	ics Afford Su	perior Pr	otection
1	against Doxorubicin-In				ygen and	Nitrogen i	ntermediates	", Archiv	es of
	Biochemistry and Biop Beil et al, "Helicobacte	hysics 368(2	2):421-428 (1999)	Clutathiana in G	actric Enit	halial Cal	le" Digestive	Diceases	and
	Sciences 45(9):1769-17		iuces intracentiai	Giutatinone in G	asure Epn	nenai Cer	is , Digestive	Discases	and
	Chung et al, "Protective	e effects of l	nemin and tetrakis	(4-benzoic acid)r	orphyrin (	on bacteria	l mutagenes	is and mo	ouse sk
	carcinogenesis induced	by 7,12-dir	nethylbenz[a]anth	racene", Mutation	n Research	472:139-	145 (2000)		
	Obst et al. "Helicobact	er pylori cau	ises DNA damage	in gastric epithel	lial cells",	Carcinoge	nesis 21(6):	1111-111:	5 (2000
	Patel and Day, "Metall 364 (1999)	oporphyrin (	class of therapeuti	c catalytic antiox	idants", T	PS Elsevi	er Trends Jo	urnal 20(9	1):359-
	White et al, "A Highly	Stereoselec	tive Synthesis of I	Epothilone B", J.	Org. Chen	n. 64:684-	685 (1999)		
-	Batinic-Haberle et al. "	The Ortho I	Effect Makes Man	ganic Meso-Tetra	kis-(N-M	ethylpyrid	inium-2-YL)	(MnTM-2	2-PyP <sup>5+</sup>
	A Powerful And Useful Council Meeting, The	l Superoxid	e Dismutase Mim	ic", Oxygen '97, 🛚	Γhe 4 <sup>m</sup> An	nual Meet	ing of The O	xygen So	ciety,
Examiner				Date Consid	ered				